1月9日 - ** 药物开发商Aquestive Therapeutics AQST.O股价盘前下跌44%至3.49美元
** 该公司称收到了美国食品及药物管理局的一封信，信中强调了其新型过敏治疗药物Anaphylm存在的问题
** 该公司称，美国食品和药物管理局对 Anaphylm 的标签和营销问题提出了担忧，导致谈判推迟
** AQST 的 Anaphylm 是一种含有肾上腺素的可溶解薄膜，用于治疗严重过敏反应 - AQST
** 预计 FDA 将在 1 月 31 日（预定行动日期）之前对 Anaphylm 做出决定
** 该公司称，如果获得批准，它将成为肾上腺素自动注射器的首个口服替代品
** 截至上次收盘，该公司股价在过去一年中上涨了约 81%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.